Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Rhythm Pharmaceuticals (1RV) vs. Competitors

2 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:1RVRhythm PharmaceuticalsEUR 107.00EUR 7.52B-41.0528.14%Strong BuyUnlock the DE:1RV analyst price target with TipRanks PremiumDE:1RVUnlock the DE:1RV top-analyst price target with TipRanks Premium
QUREuniQure$20.30$1.42B-5.73-31.67%Strong BuyUnlock the QURE analyst price target with TipRanks PremiumDE:1RV vs QUREUnlock the QURE top-analyst price target with TipRanks Premium
VKTXViking Therapeutics$26.17$3.34B-4.85-30.69%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumDE:1RV vs VKTXUnlock the VKTX top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$17.36$1.24B-4.45-49.68%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumDE:1RV vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
MBXMBX Biosciences, Inc.$53.42$2.65B-17.46102.66%Strong BuyUnlock the MBX analyst price target with TipRanks PremiumDE:1RV vs MBXUnlock the MBX top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.79$1.58B-3.89-54.65%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumDE:1RV vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:1RVRhythm Pharmaceuticals107.0023.0027.38%
QUREuniQure20.30-7.65-27.37%
VKTXViking Therapeutics26.17-9.87-27.39%
GPCRStructure Therapeutics, Inc. Sponsored ADR17.36-19.15-52.45%
MBXMBX Biosciences, Inc.53.4226.0395.03%
KLRAKailera Therapeutics, Inc.11.79-14.21-54.65%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts